A multiple sclerosis drug for heart failure
Coronary heart disease is the leading cause of death in developed countries with millions of cases in Europe alone. It is associated with decreased blood flow to the heart, which may lead to heart attacks. To address cardiac muscle repair, which is the key problem after a heart attack, the EU-funded ReDHeaD project will test the FDA-approved drug copaxone, which is used in the treatment of multiple sclerosis. Preclinical data demonstrate significant improvement in heart function parameters following copaxone administration. Researchers will prepare for clinical trials to validate the efficacy of the drug in humans and undertake all the necessary regulatory and commercialisation activities for its rapid clinical translation.
Fields of science
Funding SchemeERC-POC-LS - ERC Proof of Concept Lump Sum Pilot
See on map